New telitacicept deal aims to advance MG therapy outside China
Vor Bio has signed an exclusive license agreement to develop and market Remegen’s telitacicept — a B-cell-targeting candidate…
Articles by Margarida Maia, PhD
Combined procedure better as myasthenic crisis treatment: Study
Plasma exchange — a procedure that clears antibodies, such as those that cause myasthenia gravis (MG), from the blood…
Dosing starts in study of potential myasthenia gravis therapy S-1117
Dosing has started in the first group of healthy adults participating in a clinical study of S-1117, a candidate treatment…
Tacrolimus found effective for most children with juvenile MG: Study
Tacrolimus, an immunosuppressant sometimes used off-label to treat adults with myasthenia gravis (MG), eased symptoms of the disease in…
More severe MG linked to exacerbation, healthcare use: Study
People with more severe myasthenia gravis (MG) have a greater likelihood of experiencing episodes of exacerbation, when symptoms worsen…
Onset of symptoms in MG more likely in summer, study reports
Myasthenia gravis (MG) may be more likely to begin manifesting in the summer, with the onset of symptoms more…
COVID-19 pandemic challenged mood of myasthenia gravis patients
The COVID-19 pandemic caused emotional challenges for many people with myasthenia gravis (MG) in Australia, but how well their…
Enspryng is safe, but clinical benefit ‘small’ in gMG, trial data show
Enspryng (satralizumab), tested by Chugai Pharmaceutical as a treatment for generalized myasthenia gravis (gMG), eased disease symptoms and…
Genetic predisposition to MG raises risk for Graves’ disease, Hashimoto’s
People who are genetically predisposed to myasthenia gravis (MG) are more likely to develop Graves’ disease and Hashimoto’s thyroiditis,…
Cyrus picks CYR212 as clinical candidate for IgG-driven diseases
Cyrus Biotechnology has selected CYR212 as its clinical development candidate for myasthenia gravis (MG) and other autoimmune diseases…